Thomas Keane

Thomas Keane, MD, received his medical degree from the National University of Ireland, and completed his fellowship at the Royal College of Surgeons in Dublin, Ireland. Dr. Keane is a nationally and internationally known expert on the treatment of prostate cancer and other GU malignancies. An active researcher, Dr. Keane has conducted numerous clinical and pre-clinical trial studies. He is well known for his work on testing new therapies in GU malignancies and holds a U.S. patent on boron neutron capture therapy used for prostate cancer. His other focus has been on sphingolipids derivatives and their use as anti-cancer treatments. Dr. Keane is also interested in resistance mediators and has active projects on prostate cancer imaging using radio-labeled monoclonal antibodies and vitamin deficiencies in prostate cancer. With prostate cancer ranking as one of the state’s most common malignancies in men, he hopes to incorporate prevention with the latest initiatives in hormonal management and other therapies. Dr. Keane’s research has led to publication of more than 120 articles peer-reviewed in such journals as Cancer Research, The Journal of Urology, Urologic Oncology, and the Journal of Clinical Investigation.